Post Liver Transplantation Management and Complications

Zakim and Boyer's Hepatology

Volumn , Issue , 2006, Pages 961-974

  Gaglio, Paul J ^a   Brown, Robert S ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33947325552     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3258-8.50056-5     Document Type: Chapter

References (92)

1. http://www.UNOS.org.
2. Oh CK, Sanfey HA, Pelletier SJ, et al. Related articles, implication of advanced donor age on the outcome of liver transplantation. Clin Transplant 2000, 14:386-390.
3. Rull R, Vidal O, Momblan D, et al. Evaluation of potential liver donors: limits imposed by donor variables in liver transplantation. Liver Transpl 2003, 9:389-393.
4. Busuttil RW, Tanaka K The utility of marginal donors in liver transplantation. Liver Transpl 2003, 9:651-663.
5. Cescon M, Grazi GL, Ercolani G, et al. Long-term survival of recipients of liver grafts from donors older than 80 years: is it achievable?. Liver Transpl 2003, 9:1174-1180.
6. Zhao Y, Lo CM, Liu CL, Fan ST Use of elderly donors (60 years) for liver transplantation. Asian J Surg 2004, 27:114-119.
7. Machicao VI, Bonatti H, Krishna M, et al. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004, 77:84-92.
8. Russo MW, Brown RS Adult living donor liver transplantation. Am J Transplant 2004, 4:458-465.
9. Brown RS, Russo MW, Lai M, et al. A survey of liver transplantation from living adult donors in the United States. N Engl J Med 2003, 348:818-825.
10. Marcos A, Fisher RA, Ham JM, et al. Liver regeneration and function in donor and recipient after right lobe adult to adult living donor liver transplantation. Transplantation 2000, 69:1375-1379.
11. Shiffman ML, Brown RS, Olthoff KM, et al. Living donor liver transplantation: summary of a conference at the National Institutes of Health. Liver Transpl 2002, 8:174-188.
12. Emond JC, Renz JF, Ferrell LD, et al. Functional analysis of grafts from living donors. Implications for the treatment of older recipients. Ann Surg 1996, 224:544-552.
13. Otero A, Gomez-Gutierrez M, Suarez F, et al. Liver transplantation from Maastricht category 2 non-heart-beating donors: a source to increase the donor pool?. Transplant Proc 2004, 36:747-750.
14. Abt PL, Desai NM, Crawford MD, et al. Survival following liver transplantation from non-heart-beating donors. Ann Surg 2004, 239:87-92.
15. Reich DJ, Munoz SJ, Rothstein KD, et al. Controlled non-heart-beating donor liver transplantation: a successful single center experience, with topic update. Transplantation 2000, 70:1159-1166.
16. Tisone G, Manzia TM, Zazza S, et al. Marginal donors in liver transplantation. Transplant Proc 2004, 36:525-536.
17. Montalti R, Nardo B, Bertelli R, et al. Donor pool expansion in liver transplantation. Transplant Proc 2004, 36:520-522.
18. Verran D, Kusyk T, Painter D, et al. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transpl 2003, 9:500-505.
19. Urena MA, Moreno Gonzalez E, Romero CJ, et al. An approach to the rational use of steatotic donor livers in liver transplantation. Hepatogastroenterology 1999, 46:1164-1173.
20. Arenas JI, Vargas HE, Rakela J The use of hepatitis C-infected grafts in liver transplantation. Liver Transpl 2003, 9:S48-S51.
21. Saab S, Chang AJ, Comulada S, et al. Outcomes of hepatitis C-and hepatitis B core antibody-positive grafts in orthotopic liver transplantation. Liver Transpl 2003, 9:1053-1061.
22. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001, 33:464-470.
23. Freeman RB, Wiesner RH, Edwards E, et al. United Network for Organ Sharing Organ Procurement and Transplantation Network Liver and Transplantation Committee. Results of the first year of the new liver allocation plan. Liver Transpl 2004, 10:7-15.
24. Onaca NN, Levy MF, Sanchez EQ, et al. A correlation between the pretransplantation MELD score and mortality in the first two years after liver transplantation. Liver Transpl 2003, 9:117-123.
25. Jain A, Kashyap R, Marsh W, et al. Reasons for long-term use of steroid in primary adult liver transplantation under tacrolimus. Transplantation 2001, 71:1102-1106.
26. Conti F, Morelon E, Calmus Y. Immuosuppressive therapy in liver transplantation. J Hepatol 2003, 39:664-678.
27. Tector AJ, Fridell JA, Mangus RS, et al. Promising early results with immunosuppression using rabbit anti-thymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipients. Liver Transpl 2004, 10:404-407.
28. Liu CL, Fan ST, Lo CM, et al. Interleukin 2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transpl 2004, 10:728-733.
29. Lilly LB, Grant D Optimization of ciclosporin for liver transplantation. Transplant Proc 2004, 36:267S-270S.
30. Herrero JI, Quiroga J, Sangro B, et al. Conversion of liver transplant recipients on ciclosporin with renal impairment to mycophenolate mofetil. Liver Transpl Surg 1999, 5:414.
31. Trotter JF Sirolimus in liver transplantation. Transplant Proc 2003, 35:193-200.
32. Nair S, Eason J, Loss G. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl 2003, 9:126-129.
33. Schemmer P, Mehrabi A, Kraus T, et al. New aspects on reperfusion injury to liver - impact of organ harvest. Nephrol Dial Transplant 2004, 19:26-35.
34. Sieders E, Peeters PM, TenVergert EM, et al. Early vascular complications after pediatric liver transplantation. Liver Transpl 2000, 6:326-332.
35. Bhattacharjya S, Gunson BK, Mirza DF, et al. Delayed hepatic artery thrombosis in adult orthotopic liver transplantation - a 12-year experience. Transplantation 2001, 71:1592-1596.
36. Denys A, Chevallier P, Doenz F, et al. Interventional radiology in the management of complications after liver transplantation. Eur Radiol 2004, 14:431-439.
37. Vignali C, Cioni R, Petruzzi P, et al. Role of interventional radiology in the management of vascular complications after liver transplantation. Transplant Proc 2004, 36:552-554.
38. Selzner N, Rudiger H, Graf R, Clavien PA Protective strategies against ischemic injury of the liver. Gastroenterology 2003, 125:917-936.
39. Clavien PA, Yadav S, Sindram D, Bentley RC Protective effects of ischemic preconditioning for liver resection performed under inflow occlusion in humans. Ann Surg 2000, 232:155-162.
40. Lefkowitch JH Diagnostic issues in liver transplantation pathology. Clin Liver Dis 2002, 6:555-570.
41. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002, 8:S14-S18.
42. Desai D, Desai N, Nightingale P, et al. Carriage of methicillin-resistant Staphylococcus aureus is associated with an increased risk of infection after liver transplantation. Liver Transpl 2003, 9:754-759.
43. Singh N, Gayowski T, Rihs JD, et al. Evolving trends in multiple-antibiotic-resistant bacteria in liver transplant recipients: a longitudinal study of antimicrobial susceptibility patterns. Liver Transpl 2001, 7:22-26.
44. Singh N. Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin North Am 2003, 17:113-134.
45. Fondevila C, Ghobrial RM, Fuster J, et al. Biliary complications after adult living donor liver transplantation. Transplant Proc 2003, 35:1902-1903.
46. Gopal DV, Pfau PR, Lucey MR Endoscopic management of biliary complications after orthotopic liver transplantation. Curr Treat Options Gastroenterol 2003, 6:509-515.
47. van der Bij W, Speich R Management of cytomegalovirus infection and disease after solid-organ transplantation. Clin Infect Dis 2001, 33:S32-S37.
48. Razonable RR, Burak KW, van Cruijsen H, et al. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis 2002, 35:974-981.
49. Sia IG, Wilson JA, Groettum CM, et al. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000, 181:717-720.
50. Norris S, Kosar Y, Donaldson N, et al. Cytomegalovirus infection after liver transplantation: viral load as a guide to treating clinical infection. Transplantation 2002, 74:527-531.
51. Textor SC, Taler SJ, Canznello VJ, et al. Post transplantation hypertension related to calcineurin inhibitors. Liver Transpl 2000, 6:521-530.
52. Risaliti A, Baccarani U, Vianello V, et al. Cardiovascular and metabolic complications after liver transplantation: Neoral- versus tacrolimus-based immunosuppression. Transplant Proc 2001, 33:3684-3685.
53. Charco R, Bilbao I, Chavez R, et al. Low incidence of hypercholesterolemia among liver transplant patients under tacrolimus monotherapy immunosuppression. Transplant Proc 2002, 34:1555-1556.
54. Neal DA, Alexander GJ Can the potential benefits of statins in general medical practice be extrapolated to liver transplantation?. Liver Transpl 2001, 7:1009-1014.
55. Mehra MR, Uber PA, Vivekananthan K, et al. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. J Am Coll Cardiol 2002, 40:1609-1614.
56. Sheiner PA, Magliocca JF, Bodian CA, et al. Long-term medical complications in patients surviving > 5 years after liver transplant. Transplantation 2000, 69:781-789.
57. Yoo HY, Thuluvath PJ The effect of insulin-dependent diabetes mellitus on outcome of liver transplantation. Transplantation 2002, 74:1007-1012.
58. Stockmann M, Steinmuller T, Nolting S, Neuhaus P. Posttransplant diabetes mellitus after orthotopic liver transplantation. Transplant Proc 2002, 34:1571-1572.
59. Risaliti A, Baccarani U, Vianello V, et al. Cardiovascular and metabolic complications after liver transplantation: Neoral- versus tacrolimus-based immunosuppression. Transplant Proc 2001, 33:3684-3685.
60. Varo E, Padin E, Otero E, et al. Cardiovascular risk factors in liver allograft recipients: relationship with immunosuppressive therapy. Transplant Proc 2002, 34:1553-1554.
61. Reuben A. Long-term management of the liver transplant patient: diabetes, hyperlipidemia, and obesity Liver. Transpl 2001, 7:S13-S21.
62. Yoo HY, Molmenti E, Thuluvath PJ The effect of donor body mass index on primary graft nonfunction, retransplantation rate, and early graft and patient survival after liver transplantation. Liver Transpl 2003, 9:72-78.
63. Nair S, Verma S, Thuluvath PJ Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002, 35:105-109.
64. Johnston SD, Morris JK, Cramb R, et al. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002, 73:901-906.
65. Moller S, Henriksen JH Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002, 87:9-15.
66. Cohen AJ, Stegall MD, Rosen CB, et al. Chronic renal dysfunction late after liver transplantation. Liver Transpl 2002, 8:916-921.
67. Fisher NC, Nightingale PG, Gunson BK, et al. Chronic renal failure following liver transplantation. Transplantation 1998, 66:59-66.
68. Moreno JM, Rubio E, Pons F, et al. Usefulness of mycophenolate mofetil in patients with chronic renal insufficiency after liver transplantation. Transplant Proc 2003, 35:715-717.
69. Demetris A, Adams D, Bellamy C, et al. Update of the international Banff schema for liver allograft rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. Hepatology 2000, 31:792-799.
70. Singh N, Avery RK, Munoz P, et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 2003, 36:46-52.
71. Wu G, Vilchez RA, Eidelman B, et al. Cryptococcal meningitis: an analysis among 5521 consecutive organ transplant recipients. Transpl Infect Dis 2002, 4:183-188.
72. Holmes RD, Sokol RJ Epstein-Barr virus and post-transplant lymphoproliferative disease. Pediatr Transplant 2002, 6:456-464.
73. Bueno J, Ramil C, Somoza I, et al. Treatment of monomorphic B-cell lymphoma with rituximab after liver transplantation in a child. Pediatr Transplant 2003, 7:153-156.
74. Smets F, Sokal EM Epstein-Barr virus-related lymphoproliferation in children after liver transplant: role of immunity, diagnosis, and management. Pediatr Transplant 2002, 6:280-287.
75. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-699.
76. Valero JM, Rubio E, Moreno JM, et al. De novo malignancies in liver transplantation. Transplant Proc 2003, 35:709-711.
77. Mithoefer AB, Supran S, Freeman RB Risk factors associated with the development of skin cancer after liver transplantation. Liver Transpl 2002, 8:939-944.
78. Saigal S, Norris S, Muiesan P, et al. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. Liver Transpl 2002, 8:482-487.
79. Atassi T, Thuluvath PJ Risk of colorectal adenoma in liver transplant recipients compared to immunocompetent control population undergoing routine screening colonoscopy. J Clin Gastroenterol 2003, 37:72-73.
80. Trotter JF, Brazer SR Rapid progression to high-grade dysplasia in Barrett's esophagus after liver transplantation. Liver Transpl Surg 1999, 5:332-333.
81. Loftus EV, Aguilar HI, Sandborn WJ, et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology 1998, 27:685-690.
82. Neuberger J. Recurrent primary biliary cirrhosis. Best Pract Res Clin Gastroenterol 2000, 14:669-680.
83. Wiesner RH Liver transplantation for primary sclerosing cholangitis: timing, outcome, impact of inflammatory bowel disease and recurrence of disease. Best Pract Res Clin Gastroenterol 2001, 15:667-680.
84. Molmenti EP, Netto GJ, Murray NG, et al. Incidence and recurrence of autoimmune/alloimmune hepatitis in liver transplant recipients. Liver Transpl 2002, 8:519-526.
85. Burke A, Lucey MR Non-alcoholic fatty liver disease, nonalcoholic steatohepatitis and orthotopic liver transplantation. Am J Transplant 2004, 4:686-693.
86. Mackie J, Groves K, Hoyle A, et al. Orthotopic liver transplantation for alcoholic liver disease: a retrospective analysis of survival, recidivism, and risk factors predisposing to recidivism. Liver Transpl 2001, 7:418-427.
87. Marzan A, Salizzoni M, Debernardi-Venon W, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001, 34:903-910.
88. Berenguer M, Prieto M, Rayon J, et al. Natural history of clinically compensated hepatitis C virus related graft cirrhosis after liver transplantation. Hepatology 2000, 32:852-858.
89. Gaglio PJ, Malireddy S, Levitt BS, et al. Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transpl 2003, 9:1028-1035.
90. Crippin JS, McCashland T, Terrault N, et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002, 8:350-355.
91. Everson GT Treatment of chronic hepatitis C in patients with decompensated cirrhosis. Rev Gastroenterol Disord 2004, 4:S31-S38.
92. Gane E. Treatment of recurrent hepatitis C. Liver Transpl 2002, 8:S28-S37.